about
The history of neuromyelitis opticaWhat do we know about brain contrast enhancement patterns in neuromyelitis optica?Aquaporin-4 autoimmunityInternational consensus diagnostic criteria for neuromyelitis optica spectrum disordersMolecular pathogenesis of neuromyelitis opticaConventional and advanced imaging in neuromyelitis opticaMRI characteristics of neuromyelitis optica spectrum disorder: an international updateTreatment of neuromyelitis optica: state-of-the-art and emerging therapiesMolecular disruptions of the panglial syncytium block potassium siphoning and axonal saltatory conduction: pertinence to neuromyelitis optica and other demyelinating diseases of the central nervous system.The expanded spectrum of neuromyelitis optica: evidences for a new definition.Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders.Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography.Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status.Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later.Patient with neuromyelitis optica and inflammatory demyelinating lesions comprising whole spinal cord from C2 level till conus: case reportNeuromyelitis optica - an update: 2007-2009Differential diagnosis of neuromyelitis optica spectrum disorders.Serum thyroid-stimulating hormone and anti-thyroglobulin antibody are independently associated with lesions in spinal cord in central nervous system demyelinating diseases.Conventional brain MRI in neuromyelitis optica.AQP4 autoantibody assay performance in clinical laboratory service.Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritisRituximab as a first-line preventive treatment in pediatric NMOSDs: Preliminary results in 5 children.Regulation of neurovascular coupling in autoimmunity to water and ion channelsUpdate on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.New insights into neuromyelitis opticaMolecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytesAcquired demyelinating disorders of central nervous system: A pediatric cohort.Sensitive and robust luminescent profiling of anti-La and other autoantibodies in Sjogren's syndrome.Diagnostic utility of NMO/AQP4-IgG in evaluating CNS inflammatory disease in Thai patients.Brain abnormalities in neuromyelitis optica spectrum disorder.Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorderClinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report.Protective role of brain water channel AQP4 in murine cerebral malaria.A descriptive study of prevalence, clinical features and other findings of neuromyelitis optica and neuromyelitis optica spectrum disorder in Khuzestan Province, Iran.Paraneoplastic and other autoimmune disorders of the central nervous system.Effects of age and sex on aquaporin-4 autoimmunity.Pediatric multiple sclerosis: current concepts and consensus definitions.A clinical approach to diagnosis of autoimmune encephalitis.A nationwide survey of pediatric acquired demyelinating syndromes in Japan.
P2860
Q21245248-C15A3503-4ECD-4781-A516-D21DA776FC47Q26776278-D5594FF1-512D-4985-B039-65EA55571C52Q26799559-ACAA7C3E-F513-4542-87D0-C75DF33302ACQ26824579-AAFB3FC4-B132-40E1-9857-63B62D70E410Q27021535-33C9DF0C-27F5-493B-B059-E2CA15D7A12FQ27021822-8A493974-2D22-4C41-8DDE-AF2576F44B30Q28087067-C6DFC51D-0B40-4918-B5D7-25F1FD421FA4Q28245749-1A425B4D-E03D-46B6-9160-2A300D2FC1DDQ30474717-C0FDFD14-F207-47C7-B341-794CC7271AB4Q30573084-10246B6B-7C8F-4936-8AE2-8F0F35F812AEQ30577078-C0273F51-811F-4C49-B850-353F9F3E817AQ30649660-A15B9BF8-7818-49CD-A23E-5E3E462B3D4DQ30676331-6899872F-B0E3-4EA9-A3C3-28D85E39A182Q30975717-D079AB12-E657-4E40-A33E-AD4BF41BDE02Q33512099-3F888CFC-A62E-417E-B71B-AD26BBE63686Q33670918-0B592732-43BB-4608-B868-19F072820E07Q33812063-341F23A8-15E2-47CA-8AF2-3637FBA4547EQ34004654-CEACC896-3EFF-45B2-B8D1-303A8EA1F2E2Q34062883-145EAB7C-A345-488F-AF71-8D5103F16D76Q34368662-D19D3689-E5CF-461D-9082-20BD1B107054Q34453889-542C7E34-665D-4AD6-BF41-43B389823F5EQ34714525-926E60E9-2047-4DD3-BCA1-500DF82240A2Q35001946-D4F4FA7C-C3F2-48A4-B822-CE7E5E8779E9Q35052199-9C1845D3-31D3-40C5-96F1-E6519CFB83DCQ35228937-6EE0ED50-9861-4078-842A-CDC11AF9A780Q35539641-FB610EF1-2184-49F3-8BE5-5A5AF45469D4Q35708842-D13FDE98-DAF6-4990-90DD-00B483E9199FQ36159492-30D650FF-0474-4407-B4BF-281B1A9463C9Q36160086-5863B1A3-12C3-463F-95D6-A4941147F200Q36176684-95FE1C2F-B0F6-4974-BAE9-88B0AB65B1A6Q36457932-2707C8F3-9051-4E18-83A5-449851F4DFE1Q36490876-BC49BAA0-C54F-4B37-996B-4C3581360CCAQ36521281-30B3859F-4BFE-463C-8D7E-6E82EAAD6BA9Q36545616-E0C7DB2C-85CA-480E-917F-07DB20FC4E6CQ36582951-5AF0BC6A-0778-44CE-9F47-7788E5372639Q37052800-B10AF83A-D8F7-4944-B126-361FD2BC55E3Q37104209-A804E5F8-7D0E-4A89-A904-57D28EA0A551Q37330502-EFDB0BBD-F56E-4AE9-92FF-D7DB5ECA89DBQ37343730-2FF09153-01C0-4C5D-979C-25968F5A10D4Q37415085-EB999B6D-E9A0-4A0F-BC47-70B7D76C361A
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
CNS aquaporin-4 autoimmunity in children.
@ast
CNS aquaporin-4 autoimmunity in children.
@en
type
label
CNS aquaporin-4 autoimmunity in children.
@ast
CNS aquaporin-4 autoimmunity in children.
@en
prefLabel
CNS aquaporin-4 autoimmunity in children.
@ast
CNS aquaporin-4 autoimmunity in children.
@en
P2093
P1433
P1476
CNS aquaporin-4 autoimmunity in children.
@en
P2093
B G Weinshenker
C F Lucchinetti
H Homburger
P304
P356
10.1212/01.WNL.0000314832.24682.C6
P407
P577
2008-05-28T00:00:00Z